Related Experiment Video

Updated: Sep 21, 2026

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Maximilian Marhold1, Andreas Heinzel2, Almas Merchant1

  • 1Department of Internal Medicine I - Division of Oncology, Comprehensive Cancer Center, Medical University of Vienna.

Journal of Visualized Experiments : Jove
|June 14, 2021
PubMed

Insights

Synthetic lethal interactions offer new cancer therapy targets. This study presents a data integration workflow to identify effective drug combinations for targeting these interactions, with applications in ovarian and breast cancer.

Area of Science:

  • Genomics
  • Cancer Biology
  • Pharmacology

Background:

  • Synthetic lethality occurs when the combined loss of two genes leads to cell death, unlike the loss of either gene alone.
  • The BRCA1/2 and PARP1 interaction is a clinically validated example, with PARP1 inhibitors used for BRCA1/2-mutated cancers.
  • Numerous synthetic lethal pairs have been identified, presenting opportunities for novel cancer therapeutics.

Purpose of the Study:

  • To outline a data integration workflow for evaluating and identifying drug combinations targeting synthetic lethal interactions.
  • To leverage existing datasets for drug combination discovery in cancer therapy.
  • To assess drug combinations in the context of ovarian and breast cancer.

Main Methods:

  • Data integration of synthetic lethal interaction pairs, gene homology, drug-target links, and clinical trial information.
  • Utilizing dedicated databases for drug and target information.
  • Applying the workflow to assess drug combinations for ovarian and breast cancer.

Main Results:

  • The study outlines a comprehensive workflow for identifying potential drug combinations based on synthetic lethality.
  • Key findings from recent studies on drug combination assessment in ovarian and breast cancer are highlighted.
  • The workflow integrates diverse biological and pharmacological data for robust evaluation.

Conclusions:

  • Synthetic lethal interactions represent a promising avenue for developing targeted cancer therapies.
  • The presented data integration workflow facilitates the identification of novel drug combinations for cancer treatment.
  • This approach has potential applications in precision medicine for ovarian and breast cancer.

More Related Videos

Diagonal Method to Measure Synergy Among Any Number of Drugs12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Agonism and Antagonism: Quantification01:14

Agonism and Antagonism: Quantification

When drugs are administered, they can elicit either an agonist or antagonist effect on the body. Agonism occurs when a drug activates a specific receptor, triggering a biological response. On the other hand, antagonism happens when a drug binds to the same receptors but blocks their activation, thereby preventing a biological response.
To quantify these effects, researchers use a dose-response curve, which provides valuable information about the potency and efficacy of a drug. Potency refers to...
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...